Status:
TERMINATED
Memantine Therapy for Multiple Sclerosis
Lead Sponsor:
Clinica Universidad de Navarra, Universidad de Navarra
Collaborating Sponsors:
H. Lundbeck A/S
Conditions:
Multiple Sclerosis
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
To assess the efficacy of Memantine in improving the cognitive impairment in patients with Multiple Sclerosis (MS)
Detailed Description
Memantine is an NMDA receptor antagonist that improves cognitive and behavioural deficits in patients with Alzheimer disease, vascular dementia and mixed dementia. This study is focused in proving the...
Eligibility Criteria
Inclusion
- Patients with MS (McDonald 2002), both sex, age between 18 to 60 years old, all MS subtypes (RR, SP, PP, PR), stable.
- Patients with severe cognitive impairment defined as performing 1.5 SD below control group (matched by age and education) in 2 o more subtests based in our previous study (Sepulcre 2006):
Exclusion
- Psychiatric diseases (Cummings) depression (Hamilton \>8), drug or alcohol abuse, benzodiazepine therapy or other medical diseases.
Key Trial Info
Start Date :
September 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2008
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00638833
Start Date
September 1 2007
End Date
March 1 2008
Last Update
June 8 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Clinica Universitaria de Navarra
Pamplona, Navarre, Spain, 31008